{"entity":{"id":"acrivon-therapeutics","kind":"company","name":"Acrivon Therapeutics","aka":[],"tldr":"Acrivon Therapeutics uses a protein-activity test to pick the patients most likely to respond to its cancer drugs. Its lead drug blocks DNA damage checkpoint proteins and is being tested in womb and ovarian cancer.","summary":"Acrivon Therapeutics is a Watertown, Massachusetts clinical-stage company that pairs its AP3 (Acrivon Predictive Precision Proteomics) phosphoproteomics platform with drug candidates targeting DNA damage response and cell cycle regulation. Its lead programme, ACR-368 (prexasertib, in-licensed from Lilly), is a CHK1/CHK2 inhibitor with single-agent activity including complete responses in platinum-resistant ovarian and squamous cell cancers; the company uses its OncoSignature assay to select patients, holds FDA Fast Track designation for OncoSignature-selected endometrial and platinum-resistant ovarian cancer, and Breakthrough Device designations for the assay. ACR-2316, a dual WEE1/PKMYT1 inhibitor, is in the clinic, and ACR-6840 targets CDK11 in IND-enabling studies. Acrivon completed its Nasdaq IPO in November 2022.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://acrivon.com/"},{"label":"Pipeline","url":"https://acrivon.com/pipeline/"},{"label":"IPO closing 8-K (SEC)","url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm"}],"tags":[],"related":[],"cancers":["endometrial","ovarian"],"sections":["targeted-therapy","diagnostics"],"technologies":["kinase-inhibitors","proteomics","companion-diagnostic"],"targets":["wee1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05548296"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["IPO gross proceeds not captured from the fetched 8-K or prospectus excerpt, so the amount is omitted. Founding year not sourced."],"hq":"Watertown, MA","country":"US","companyType":"biotech","website":"https://acrivon.com/","ticker":"ACRV","stage":"public","investors":[],"funding":[{"round":"IPO","year":2022,"source":"https://www.sec.gov/Archives/edgar/data/1781174/000119312522287727/d410573d8k.htm","note":"IPO closed 17 November 2022 with a concurrent 5 million US dollar private placement to Chione; gross IPO proceeds not stated in the fetched filing"}]},"route":"/companies/acrivon-therapeutics/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"wee1","kind":"target","name":"WEE1","route":"/targets/wee1/"}],"trial":[{"id":"nct05548296","kind":"trial","name":"A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma","route":"/trials/nct05548296/"}]}}